Adjuvant nivolumab prolongs disease-free survival in patients with resected oesophageal or gastroesophageal junction cancer

Results from the CheckMate 577 study, recently published in the April 2021 issue of The New England Journal of Medicine determined that "among patients with resected oesophageal or gastroesophageal junction cancer after neoadjuvant chemotherapy, adjuvant therapy with nivolumab was associated with a significantly longer disease-free survival than placebo."  CheckMate 577 is a worldwide randomized, double-blind, placebo-controlled phase III trial evaluating treatment with nivolumab following chemotherapy and surgery for oesophageal or gastroesophageal cancer.  Patients who received nivolumab had an average disease-free survival period of 22.4 months, compared to 11months for the 262 patients receiving placebo.  

To read more about this study, click here. 

Studies mentioned: 

Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 2021;384:1191-203. DOI: 10.1056/NEJMoa2032125

Ilson DH. Adjuvant Nivolumab in Esophageal Cancer — A New Standard of Care. N Engl J Med 2021; 384:1269-1271. DOI: 10.1056/NEJMe2101983